Access and availability of orphan drugs in the United States: Advances or cruel hoaxes?

Expert Opinion on Orphan Drugs

Volumn 2, Issue 11, 2014, Pages 1147-1150

  Teagarden, J Russell ^a   Unger, Thomas F ^b   Hirsch, Gigi ^c  

^a Medical and Scientific Affairs National Organization for Rare Disorders   (United States)

^b PFIZER INC   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Access; Economics; Orphan drugs; Rare diseases; Regulation; Research

Indexed keywords

ORPHAN DRUG;

DRUG APPROVAL; DRUG COMPETITION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG LEGISLATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE FINANCING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEALTH STATUS; HUMAN; HUMAN GENOME PROJECT; PATIENT ADVOCACY; PHARMACEUTICAL CARE; QUALITY OF LIFE; RARE DISEASE; REVIEW; UNITED STATES;

EID: 84910066363     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2014.947265     Document Type: Review

References (16)

1. Haffner ME. Adopting orphan drugs - two dozen years treating rare diseases. N Engl J Med 2006;354:445-7
2. Rohde DD. The orphan drug act: an engine of innovation? At what cost? Food Drug Law J 2000;55:125-43
3. Pharmaceutical Research and Manufacturers Association. Rare diseases: a. report on orphan drugs in the pipeline. 2013. Available from: http://www.phrma.org/sites/default/files/pdf/Rare-Diseases-2013.pdf [Accessed 10 May 2014]
4. Braun MM, Farag-El-Massah S, Xu K, Coté TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 2010;9:519-22
5. Reardon S. Regulators adopt more orphan drugs. Nature 2014;508(7494):16-17
6. US Food and Drug Administration. Guidance for industry: expedited programs for serious conditions - drugs and biologics. 2014. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf [Accessed 29 June 2014]
7. FasterCures. Honest brokers for cures: how venture philanthropy groups are changing biomedical research. Available from: http://www.fastercures.org/assets/Uploads/PDF/HonestBrokers.pdf [Accessed 10 May 2014]
8. Fagnan DE, Gromatzky AA, Fernandez JM, et al. Financing drug discovery for orphan diseases. Drug Discov Today 2013.http://dx.doi.org/10.1016/j.drudis.2013.11.009 [Accessed 10 May 2014]
9. Fidler B. Cydan, the NEA startup machine, scours the globe for orphan drugs. 2013. Available from: http://www.xconomy.com/boston/2013/04/25/cydan-the-nea-startup-machine-scours-the-globe-for-orphan-drugs/ [Accessed 10 May 2014]
10. Shelly S; Pharmaceutical commerce. Pharma struggles to manage the complexity of its patient assistance programs. 2013. Available from: http://pharmaceuticalcommerce.com/brand-communications?articleid=26770 [Accessed 10 May 2014]
11. Wynberg M. Reforming patient assistance programs: perfect world meets real world. Health Aff 2009;28(3):839-42
12. Johnson PE. Patient assistance programs and patient advocacy foundations: alternatives for obtaining prescription medications. Am J Health Syst Pharm 2006;63(Suppl 7):S13-17
13. Rouse WB. Healthcare as a complex adaptive system: implications for design and management. 2008. Available from: http://ti.gatech.edu/docs/Rouse%20NAEBridge2008%20HealthcareComplexity.pdf [Accessed 2 July 2014]
14. Nightingale DJ, Srinivasan J. Beyond the lean revolution: achieving and successful and sustainable enterprise transformation. American Management Association, New York; 2011
15. European Medicines Agency. Adaptive licensing. 2014. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general-content-000601.jsp&mid=WC0b01ac05807d58ce [Accessed 7 July 2014]
16. Baird L, Hirsch G. Adaptive licensing: creating a safe haven for discussions. Scrip Regulatory Affairs 2013;10-11